Carolina Wealth Advisors LLC Purchases 1,644 Shares of The Clorox Company $CLX

Carolina Wealth Advisors LLC grew its position in The Clorox Company (NYSE:CLX) by 32.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,777 shares of the company’s stock after purchasing an additional 1,644 shares during the quarter. Carolina Wealth Advisors LLC’s holdings in Clorox were worth $814,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Hsbc Holdings PLC increased its position in Clorox by 118.8% during the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock valued at $159,699,000 after buying an additional 589,544 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in shares of Clorox by 101.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 1,083,723 shares of the company’s stock worth $130,123,000 after acquiring an additional 546,761 shares during the last quarter. KBC Group NV increased its holdings in shares of Clorox by 688.7% during the first quarter. KBC Group NV now owns 587,679 shares of the company’s stock valued at $86,535,000 after acquiring an additional 513,171 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Clorox by 412.1% in the 1st quarter. AQR Capital Management LLC now owns 598,758 shares of the company’s stock valued at $88,167,000 after purchasing an additional 481,846 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Clorox by 147.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 707,005 shares of the company’s stock worth $104,107,000 after purchasing an additional 421,453 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Trading Up 0.9%

Clorox stock opened at $123.30 on Friday. The firm has a market cap of $15.08 billion, a PE ratio of 18.91, a P/E/G ratio of 0.99 and a beta of 0.52. The Clorox Company has a 12 month low of $116.53 and a 12 month high of $171.37. The stock’s 50 day simple moving average is $122.81 and its two-hundred day simple moving average is $129.53. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX) last posted its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period in the previous year, the firm earned $1.82 EPS. The business’s quarterly revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s dividend payout ratio is presently 76.07%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Jefferies Financial Group cut their price target on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. Barclays reduced their target price on Clorox from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Tuesday, September 30th. JPMorgan Chase & Co. boosted their price target on Clorox from $133.00 to $135.00 and gave the company a “neutral” rating in a research note on Monday, September 8th. Zacks Research raised Clorox from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, UBS Group decreased their target price on Clorox from $150.00 to $134.00 and set a “neutral” rating for the company in a report on Thursday, July 17th. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Clorox presently has an average rating of “Reduce” and an average target price of $134.08.

Insider Activity at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the transaction, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. The trade was a 21.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is owned by company insiders.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.